Serpin Pharma, LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2011-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.serpinpharma.com
Clinical Trials
3
Active:0
Completed:2
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)SP16 as a Therapeutic for COVID-19 Induced ARDS
Phase 1
Terminated
- Conditions
- SARS CoV 2 InfectionPneumonia
- Interventions
- Drug: SP16 (12 mg)Drug: SP16 (6mg)Other: Placebo
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Serpin Pharma, LLC
- Target Recruit Count
- 2
- Registration Number
- NCT05135624
- Locations
- 🇺🇸
UVA Health Center, Charlottesville, Virginia, United States
SP16 Inflammatory Response Inhibition Trial
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Serpin Pharma, LLC
- Target Recruit Count
- 10
- Registration Number
- NCT04225533
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
SP16 SERPIN-like Peptide Administration in Healthy Individuals
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Serpin Pharma, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT03651089
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
News
No news found